Company news

Lifecore Biomedical, Inc. (NASDAQ:LFCR) news

Every Lifecore Biomedical, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.

View Lifecore Biomedical, Inc.

Press releases & updates

Lifecore Biomedical to Participate at CPHI Global Conference

September 3, 2026

Lifecore Biomedical Signs Agreement for Commercial Site Transfer Supporting Global Pharmaceutical Company

September 2, 2026

Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update

August 5, 2026

Lifecore Biomedical to Report Financial Results for the Second Quarter Ended June 30, 2026, on August 5, 2026

July 29, 2026

Lifecore Biomedical Signs Three New Customer Agreements

July 28, 2026

Lifecore Biomedical Signs New Agreement with Global Pharmaceutical Company

June 15, 2026

Lifecore Biomedical Signs Agreement with New Biopharmaceutical Customer

June 2, 2026

Lifecore Biomedical to Participate in William Blair 46th Annual Growth Stock Conference

May 21, 2026

Lifecore Biomedical to Participate at CDMO Live Europe

May 12, 2026

Lifecore Biomedical Reports Financial Results for the First Quarter Ended March 31, 2026, and Provides Corporate Update

May 6, 2026

Lifecore Biomedical to Report Financial Results for the First Quarter Ended March 31, 2026, on May 6, 2026

April 29, 2026

Lifecore Biomedical to Participate at 12th Annual American Biomanufacturing Summit

April 8, 2026

Lifecore Biomedical Signs Two New Agreements with Existing U.S. Biopharmaceutical Customer

March 26, 2026

Lifecore Biomedical Signs Commercial Site Transfer Agreement with Leading Medical Aesthetics Company

March 23, 2026

Lifecore Biomedical Reports Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, and Provides Corporate Update

March 16, 2026

Lifecore Biomedical to Participate in 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum

March 10, 2026

Lifecore Biomedical to Report Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, on March 16, 2026

March 9, 2026

Lifecore Biomedical Signs New Agreement with Indomo to Support Innovative Drug/Device Combination Acne Treatment

March 4, 2026

Lifecore Biomedical to Participate at DCAT Week 2026

February 17, 2026

Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)

January 19, 2026

Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 16, 2026

Lifecore Biomedical to be Added to Nasdaq Biotech Index

December 18, 2025

Lifecore Biomedical Signs CDMO Master Services Agreement with New Large Multinational Pharmaceutical Customer

December 17, 2025

Lifecore Biomedical Signs CDMO Master Services Agreement with New Large Multinational Pharmaceutical Customer

December 17, 2025

Lifecore Biomedical to Participate at 44th Annual J.P. Morgan Healthcare Conference

December 16, 2025

Lifecore Biomedical to Participate in Upcoming Investor Conferences

November 11, 2025

Lifecore Biomedical Reports Financial Results for the Three Months Ended September 30, 2025, and Provides Corporate Update

November 6, 2025

Lifecore Biomedical to Report Financial Results for the Three Months Ended September 30, 2025, on November 6, 2025

October 30, 2025

Lifecore Biomedical Selected as New Commercial Manufacturing Partner by Leading Global Pharmaceutical Company

October 29, 2025

Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market

October 28, 2025

Lifecore Biomedical to Participate at Upcoming Industry Conferences and Events

October 13, 2025

Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

September 23, 2025

Lifecore Biomedical to Participate at 24th Annual Contract Pharma Contracting and Outsourcing Conference

September 4, 2025

Lifecore Biomedical Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update

August 7, 2025

Lifecore Biomedical to Report Fourth Quarter and Fiscal Year 2025 Financial Results on August 7, 2025

July 31, 2025

Lifecore Biomedical Signs New 10-Year Commercial Manufacturing and Supply Agreement with Key Existing Customer

June 17, 2025

Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Million in Proceeds from Prior Equipment Sale

June 12, 2025

Lifecore Biomedical Names Mark DaFonseca Chief Commercial Officer

May 27, 2025

Lifecore Biomedical to Participate at Upcoming CDMO Live 2025 Conference

April 22, 2025

Lifecore Biomedical Appoints Thomas D. Salus as Chief Legal and Administration Officer

April 14, 2025

Lifecore Biomedical Reports Third Quarter Fiscal 2025 Financial Results and Provides Corporate Update

April 3, 2025

Lifecore Biomedical to Report Financial Results for Third Quarter of Fiscal 2025 on April 3, 2025

March 27, 2025

Humanetics Selects Lifecore Biomedical to Deliver CDMO Services Supporting Development of BIO 300 for the Prevention of Acute Radiation Syndrome

March 17, 2025

Lifecore Biomedical to Participate in Upcoming Investor and Industry Conferences

February 26, 2025

Lifecore Biomedical Announces Special Stockholder Meeting

January 17, 2025

Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million

January 7, 2025

Lifecore Biomedical Reports Second Quarter Fiscal 2025 Financial Results and Provides Corporate Update

January 2, 2025

Lifecore Biomedical Selected by Nirsum Labs to Provide CDMO Services Supporting Clinical Development of Innovative Opioid Use Disorder Treatment

December 19, 2024

Lifecore Biomedical Amends and Extends Revolving Credit Facility with BMO

November 26, 2024

Lifecore Biomedical to Host Virtual Investor Day Prior to Market Open on November 21, 2024

November 7, 2024

Older →